Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for DAWN

Stock NameDay One Biopharmaceuticals Inc
TickerDAWN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS23954D1090

Show aggregate DAWN holdings

News associated with DAWN

Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 12-Month Low Following Analyst Downgrade
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Wednesday after Needham & Company LLC lowered their price target on the stock from $18.00 to $16.00. Needham & Company LLC currently has a buy rating on the stock. Day One Biopharmaceuticals traded as low […] - 2025-08-07 02:46:44
Allianz Asset Management GmbH Buys Shares of 25,000 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Allianz Asset Management GmbH bought a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) in the 1st quarter, HoldingsChannel.com reports. The firm bought 25,000 shares of the company’s stock, valued at approximately $198,000. A number of other hedge funds have also made changes to their positions in DAWN. Wealth Enhancement […] - 2025-08-05 04:26:54
Arizona State Retirement System Reduces Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Arizona State Retirement System lessened its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 8.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,902 shares of the company’s stock after selling 1,471 shares during the quarter. Arizona State Retirement […] - 2025-07-24 04:38:49
Alps Advisors Inc. Lowers Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Alps Advisors Inc. lowered its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 10.1% during the first quarter, HoldingsChannel.com reports. The firm owned 73,343 shares of the company’s stock after selling 8,206 shares during the period. Alps Advisors Inc.’s holdings in Day One Biopharmaceuticals were worth $582,000 at the end […] - 2025-07-15 06:25:18
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $29.00 Average Price Target from Brokerages
Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have been given a consensus rating of “Buy” by the seven analysts that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year […] - 2025-07-14 02:56:48
Analysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Price Target at $30.57
Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have been given a consensus recommendation of “Buy” by the eight analysts that are covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 […] - 2025-06-19 02:46:56
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 15.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,579 shares of the company’s stock after buying […] - 2025-06-11 05:14:48
Two Sigma Investments LP Lowers Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Two Sigma Investments LP lessened its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 33.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 271,776 shares of the company’s stock after selling 135,725 shares during the quarter. Two Sigma […] - 2025-05-30 04:51:01
Deutsche Bank AG Buys 35,460 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Deutsche Bank AG raised its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 11.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 358,920 shares of the company’s stock after buying an additional 35,460 shares during the […] - 2025-05-20 05:12:56
Mariner LLC Sells 10,376 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Mariner LLC lessened its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 47.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 11,669 shares of the company’s stock after selling 10,376 shares during the period. Mariner LLC’s holdings in Day One Biopharmaceuticals were worth $148,000 as of its most recent filing with […] - 2025-05-08 04:40:46
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up Following Earnings Beat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $6.99, but opened at $7.52. Day One Biopharmaceuticals shares last traded at $6.64, with a volume of 935,489 shares trading hands. The company reported ($0.35) earnings […] - 2025-05-08 03:12:49
Hsbc Holdings PLC Makes New Investment in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Hsbc Holdings PLC acquired a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 38,583 shares of the company’s stock, valued at approximately $481,000. Several other hedge funds also […] - 2025-05-07 04:56:57
Wells Fargo & Company MN Sells 4,744 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Wells Fargo & Company MN cut its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 8.4% during the 4th quarter, Holdings Channel reports. The firm owned 51,735 shares of the company’s stock after selling 4,744 shares during the period. Wells Fargo & Company MN’s holdings in Day One Biopharmaceuticals were […] - 2025-05-02 04:24:48
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $32.29 Average Target Price from Analysts
Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have been given an average rating of “Buy” by the eight analysts that are currently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average […] - 2025-04-30 02:34:47
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Acquired by Fmr LLC
Fmr LLC increased its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 73.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,887,467 shares of the company’s stock after purchasing an additional 5,475,087 shares […] - 2025-04-14 05:15:07
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Corebridge Financial Inc.
Corebridge Financial Inc. reduced its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 7.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 25,805 shares of the company’s stock after selling 1,948 shares during the quarter. Corebridge Financial Inc.’s holdings in Day […] - 2025-04-11 05:40:56
Wellington Management Group LLP Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Wellington Management Group LLP raised its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 1.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 731,303 shares of the company’s stock after purchasing an additional 9,722 shares during the quarter. Wellington Management […] - 2025-04-10 06:06:51
Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Cut to $27.00 by Analysts at The Goldman Sachs Group
Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price objective trimmed by The Goldman Sachs Group from $39.00 to $27.00 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also issued reports on DAWN. JPMorgan Chase & Co. dropped their […] - 2025-03-26 04:38:43
Charles Schwab Investment Management Inc. Raises Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Charles Schwab Investment Management Inc. boosted its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 5.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 535,501 shares of the company’s stock after buying an additional 28,053 shares during the period. Charles Schwab Investment Management Inc.’s […] - 2025-03-25 05:13:03
Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $34.00 at JPMorgan Chase & Co.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) had its target price dropped by JPMorgan Chase & Co. from $39.00 to $34.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 273.63% from the company’s current […] - 2025-03-07 04:50:44
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low Following Weak Earnings
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) hit a new 52-week low on Wednesday after the company announced weaker than expected quarterly earnings. The stock traded as low as $10.06 and last traded at $10.54, with a volume of 436845 shares. The stock had previously closed at $11.82. The company reported ($0.69) earnings […] - 2025-02-27 07:08:59
Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $43.00 Price Target at The Goldman Sachs Group
Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price objective decreased by The Goldman Sachs Group from $48.00 to $43.00 in a research note released on Monday morning,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock. Several other analysts have also issued reports on DAWN. Needham & Company LLC […] - 2025-02-11 06:28:49

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc DAWN holdings

DateNumber of DAWN Shares HeldBase Market Value of DAWN SharesLocal Market Value of DAWN SharesChange in DAWN Shares HeldChange in DAWN Base ValueCurrent Price per DAWN Share HeldPrevious Price per DAWN Share Held
2025-11-12 (Wednesday)12,896DAWN holding decreased by -42USD 133,345DAWN holding decreased by -693USD 133,345-42USD -693 USD 10.34 USD 10.36
2025-11-11 (Tuesday)12,938USD 134,038DAWN holding increased by 2588USD 134,0380USD 2,588 USD 10.36 USD 10.16
2025-11-10 (Monday)12,938USD 131,450DAWN holding increased by 5563USD 131,4500USD 5,563 USD 10.16 USD 9.73002
2025-11-07 (Friday)12,938USD 125,887DAWN holding increased by 9574USD 125,8870USD 9,574 USD 9.73002 USD 8.99003
2025-11-06 (Thursday)12,938DAWN holding decreased by -462USD 116,313DAWN holding decreased by -6163USD 116,313-462USD -6,163 USD 8.99003 USD 9.14
2025-11-05 (Wednesday)13,400USD 122,476DAWN holding increased by 24656USD 122,4760USD 24,656 USD 9.14 USD 7.3
2025-11-04 (Tuesday)13,400DAWN holding decreased by -84USD 97,820DAWN holding decreased by -748USD 97,820-84USD -748 USD 7.3 USD 7.31
2025-11-03 (Monday)13,484DAWN holding decreased by -84USD 98,568DAWN holding decreased by -2378USD 98,568-84USD -2,378 USD 7.31 USD 7.44001
2025-10-31 (Friday)13,568USD 100,946DAWN holding increased by 5427USD 100,9460USD 5,427 USD 7.44001 USD 7.04002
2025-10-30 (Thursday)13,568USD 95,519USD 95,5190USD 0 USD 7.04002 USD 7.04002
2025-10-29 (Wednesday)13,568USD 95,519DAWN holding decreased by -3934USD 95,5190USD -3,934 USD 7.04002 USD 7.32997
2025-10-28 (Tuesday)13,568DAWN holding increased by 126USD 99,453DAWN holding decreased by -1362USD 99,453126USD -1,362 USD 7.32997 USD 7.5
2025-10-27 (Monday)13,442USD 100,815DAWN holding increased by 134USD 100,8150USD 134 USD 7.5 USD 7.49003
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of DAWN by Blackrock for IE00B3VWM098

Show aggregate share trades of DAWN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-12SELL-4210.44010.030 10.071USD -423 9.14 Loss of -39 on sale
2025-11-06SELL-4629.7408.967 9.045USD -4,179 9.13 Profit of 39 on sale
2025-11-04SELL-847.4907.108 7.146USD -600 9.14 Profit of 167 on sale
2025-11-03SELL-847.6207.235 7.274USD -611 9.15 Profit of 157 on sale
2025-10-28BUY1267.3307.480 7.465USD 941 9.19
2025-10-24SELL-427.4907.610 7.598USD -319 9.21 Profit of 68 on sale
2025-10-15BUY2527.7807.785 7.784USD 1,962 9.28
2025-10-02BUY427.4307.475 7.470USD 314 9.29
2025-09-30BUY847.0507.110 7.104USD 597 9.32
2025-09-11BUY1687.3707.390 7.388USD 1,241 9.39
2025-08-21SELL-426.9807.000 6.998USD -294 9.41 Profit of 101 on sale
2025-07-31BUY1266.7106.870 6.854USD 864 9.44
2025-06-30SELL-846.5006.555 6.549USD -550 9.79 Profit of 272 on sale
2025-06-25SELL-426.4406.500 6.494USD -273 9.86 Profit of 141 on sale
2025-06-20SELL-846.3206.465 6.451USD -542 9.93 Profit of 292 on sale
2025-05-23BUY426.2706.315 6.311USD 265 10.47
2025-05-19SELL-426.4806.640 6.624USD -278 10.61 Profit of 167 on sale
2025-05-15SELL-1266.1606.235 6.228USD -785 10.69 Profit of 562 on sale
2025-05-12SELL-426.5807.020 6.976USD -293 10.80 Profit of 161 on sale
2025-05-09SELL-426.4506.910 6.864USD -288 10.84 Profit of 167 on sale
2025-04-30SELL-427.7807.805 7.802USD -328 11.08 Profit of 138 on sale
2025-04-24SELL-847.9007.910 7.909USD -664 11.21 Profit of 278 on sale
2025-04-17SELL-426.8406.880 6.876USD -289 11.43 Profit of 191 on sale
2025-04-15SELL-1267.1907.420 7.397USD -932 11.52 Profit of 520 on sale
2025-04-14SELL-1267.2207.410 7.391USD -931 11.57 Profit of 527 on sale
2025-04-09SELL-1687.2707.520 7.495USD -1,259 11.72 Profit of 711 on sale
2025-04-07SELL-2947.0207.360 7.326USD -2,154 11.84 Profit of 1,326 on sale
2025-04-04SELL-4207.2207.700 7.652USD -3,214 11.89 Profit of 1,780 on sale
2025-03-31BUY427.9307.960 7.957USD 334 12.04
2025-03-19SELL-848.2808.349 8.342USD -701 12.44 Profit of 344 on sale
2025-03-14SELL-2528.1208.890 8.813USD -2,221 12.61 Profit of 958 on sale
2025-03-13SELL-848.7008.850 8.835USD -742 12.67 Profit of 322 on sale
2025-03-12SELL-1,4288.7908.960 8.943USD -12,771 12.72 Profit of 5,401 on sale
2025-03-07SELL-848.6709.070 9.030USD -759 12.92 Profit of 326 on sale
2025-03-06SELL-1269.1009.480 9.442USD -1,190 12.97 Profit of 445 on sale
2025-03-03SELL-428.2509.258 9.157USD -385 13.17 Profit of 169 on sale
2025-02-28SELL-2529.0609.540 9.492USD -2,392 13.24 Profit of 944 on sale
2025-02-26SELL-429.87011.090 10.968USD -461 13.36 Profit of 100 on sale
2025-02-25SELL-12611.82012.380 12.324USD -1,553 13.38 Profit of 133 on sale
2025-02-18BUY21011.93012.540 12.479USD 2,621 13.53
2025-02-13BUY4212.21012.260 12.255USD 515 13.61
2025-02-12BUY4212.13012.210 12.202USD 512 13.64
2025-02-11BUY12611.92011.940 11.938USD 1,504 13.68
2025-02-06BUY37812.51012.650 12.636USD 4,776 13.78
2025-01-27BUY4212.77012.870 12.860USD 540 14.04
2024-12-30BUY21012.58012.850 12.823USD 2,693 14.22
2024-12-06BUY16813.75013.840 13.831USD 2,324 14.30
2024-12-05BUY4213.46013.890 13.847USD 582 14.32
2024-12-04BUY21013.80014.460 14.394USD 3,023 14.34
2024-11-29BUY21013.93014.009 14.001USD 2,940 14.41
2024-11-27BUY16813.72013.780 13.774USD 2,314 14.47
2024-11-26BUY4213.54013.790 13.765USD 578 14.51
2024-11-21BUY21013.34013.700 13.664USD 2,869 14.67
2024-11-20BUY12613.62013.710 13.701USD 1,726 14.73
2024-11-18BUY50413.01013.760 13.685USD 6,897 14.91
2024-11-12BUY33615.64015.739 15.729USD 5,285 14.87
2024-11-08BUY21016.39016.760 16.723USD 3,512 14.76
2024-11-07BUY63015.76016.140 16.102USD 10,144 14.68
2024-11-06BUY8415.43015.740 15.709USD 1,320 14.62
2024-10-31BUY4214.72016.230 16.079USD 675 14.51
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of DAWN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19101,088200226,93644.5%
2025-09-18103,5560310,49633.4%
2025-09-17103,0720365,04428.2%
2025-09-1679,1620291,00127.2%
2025-09-1569,3160266,55426.0%
2025-09-1286,7160211,87140.9%
2025-09-11128,9320293,67643.9%
2025-09-1079,3140382,08720.8%
2025-09-0955,4090163,76433.8%
2025-09-0890,6490294,16730.8%
2025-09-05105,3071,514322,53132.7%
2025-09-0497,40930,755230,33442.3%
2025-09-03149,4590598,85925.0%
2025-09-02131,0410357,91136.6%
2025-08-29103,0060253,07940.7%
2025-08-28142,8080342,96441.6%
2025-08-27279,7330495,58156.4%
2025-08-26244,3710437,85255.8%
2025-08-25164,7430326,39150.5%
2025-08-22185,892574527,33935.3%
2025-08-21133,0040203,71765.3%
2025-08-20160,0890295,17254.2%
2025-08-19295,0701,302645,89345.7%
2025-08-18173,7266669,91225.9%
2025-08-15246,98116565,73843.7%
2025-08-14158,7530313,52150.6%
2025-08-13261,892310805,12032.5%
2025-08-121,015,4022,8001,643,56961.8%
2025-08-11162,783117830,07919.6%
2025-08-08365,15897619,82258.9%
2025-08-07745,06610,4881,183,69262.9%
2025-08-062,444,048246,0934,453,51554.9%
2025-08-05812,7421,3862,254,65936.0%
2025-08-04231,56701,401,58116.5%
2025-08-01226,7220332,72868.1%
2025-07-31325,10772411,82278.9%
2025-07-30190,5930263,03072.5%
2025-07-29244,7096,529435,05556.2%
2025-07-28378,4340572,95766.0%
2025-07-25327,639298629,60252.0%
2025-07-24297,0430756,30239.3%
2025-07-23260,5480754,37334.5%
2025-07-22112,746374273,43241.2%
2025-07-21206,339971410,51650.3%
2025-07-18339,6445,155636,36153.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.